Project Grant R00DE030971
- This Project Grant award of $889,616.00 from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to investigate the cellular and molecular mechanisms by which specific RNAs and proteins enriched in neural crest cell (NCC) protrusions promote NCC migration. The research aims to determine the transcriptome and proteome of NCC projections and test their function, as well as examine the localization...
- This Project Grant award, provided by the National Institute of Dental and Craniofacial Research (NIDCR), supports research under the Oral Diseases and Disorders Research program (CFDA 93.121) on the role of primary cilia and the C2CD3 protein in craniofacial skeletal development. The $646,212 award to the Children's Hospital Medical Center in Cincinnati, Ohio will fund experiments to determine if skeletal differentiation is impaired in human induced pluripotent stem cell-derived neural crest...
- This $453,750 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to investigate the genetic and cellular mechanisms underlying craniosynostosis, a common craniofacial birth defect. The research team at Boston University Medical Campus will use a zebrafish model to study the role of the ERF transcription factor in normal skull development and how its reduction...
- This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $160,000.00 to Northwestern University to conduct research on the "REGULATION OF NEURAL CREST FORMATION BY POU5F TRANSCRIPTION FACTORS." The research aims to advance the understanding of neural crest cells and their role in vertebrate development, with potential implications for addressing congenital defects...
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to establish a novel zebrafish model of syndromic craniosynostosis. The $313,000 award to Emory University will enable comprehensive phenotypic, mechanistic, and genetic analyses of the craniosynostosis mutant zebrafish to better understand the underlying pathological mechanisms. The research aims to identify...
- This federal Project Grant award, valued at $294,000 and spanning September 2024 to September 2026, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program. The grant supports research to understand the mechanisms of craniofacial cartilage differentiation from human neural crest stem cells, with the goal of developing tissue engineering approaches to repair birth defects and injuries to the head and...
- This federal Project Grant award of $315,289.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program. The award supports research to investigate the role of the SIX1 transcription factor in neural crest cell fate determination within the mouse mandibular arch. The project aims to identify changes in cell populations and the impact of SIX1 variants linked to Branchio-Oto-Renal syndrome on...
- This Project Grant award, totaling $493,458, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program. The grant aims to investigate the role of ARID1 proteins in regulating cranial neural crest cell (CNCC) development, which is critical for proper craniofacial formation. The project will examine how ARID1A and ARID1B, subunits of the chromatin remodeling complex BAF, dynamically...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $320,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Marshfield Clinic, Inc. The project aims to identify genomic regulatory elements involved in the development of oral clefts, a common birth defect. Specifically, the research will 1) identify enhancers that drive gene expression in human embryonic palatal mesenchyme cells, 2) determine which enhancers regulate transcription...
- The federal Project Grant award titled "FROM CREST TO BONE: UNDERSTANDING NEURAL CREST SKELETOGENIC CAPACITY ALONG THE NEURAL AXIS" is funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The $162,281 grant, awarded on August 6, 2025, supports research at the California Institute of Technology (Caltech) to investigate the fundamental gene regulatory networks driving neural...
UNDERSTANDING RNA POLYMERASE III TRANSCRIPTION IN NEURAL CREST CELL AND CRANIOFACIAL DEVELOPMENT - PROJECT SUMMARY CRANIOFACIAL ANOMALIES ACCOUNT FOR ONE THIRD OF ALL BIRTH DEFECTS AND ARE A SIGNIFICANT CAUSE OF INFANT MORTALITY. NEURAL CREST CELLS (NCC) GIVE RISE TO THE MAJORITY OF CRANIOFACIAL BONE, CARTILAGE, AND CONNECTIVE TISSUE AND UN- DERSTANDING THEIR DEVELOPMENT IS CRUCIAL FOR ADVANCING THE PREVENTION OF CRANIOFACIAL BIRTH DEFECTS. DISRUPTIONS IN NCC DEVELOPMENT ARE KNOWN TO UNDERLIE SEVERAL CRANIOFACIAL DISORDERS INCLUDING TREACHER COLLINS SYNDROME, WHICH IS CAUSED BY MUTATIONS IN TCOF1, POLR1B, POLR1C, AND POLR1D. POLR1C AND POLR1D ARE SUBU- NITS OF BOTH RNA POLYMERASES (POL) I AND III AND ARE IMPORTANT FOR TRANSCRIPTION OF RIBOSOMAL RNA. I PREVIOUSLY DEMONSTRATED IN POLR1C AND POLR1D ZEBRAFISH MODELS THAT RIBOSOMAL RNA TRANSCRIPTION IS REDUCED LEADING TO TP53-DEPENDENT CELL DEATH OF NCC PROGENITORS WHICH RESULTS IN CRANIOFACIAL ANOMALIES. HOWEVER, HOW GLOBAL DISRUPTIONS IN POLR1C AND POLR1D SPECIFICALLY AFFECT NCC DEVELOPMENT REMAINS UNRESOLVED AND THE CONTRIBUTION OF POL III, WHICH TRANSCRIBES NON-CODING RNAS INCLUDING 5S RIBOSOMAL RNA AND TRANSFER RNAS, TO CRANIOFACIAL DEVELOPMENT IS NOT KNOWN. I HYPOTHESIZE THAT IN ADDITION TO DISRUPTION OF POL I TRANSCRIPTION IN THE PATHOGENESIS OF TREACHER COLLINS SYNDROME, POL III TRANSCRIPTION IS ALSO DISRUPTED AND CONTRIBUTES TO THE TISSUE-SPECIFIC PHE- NOTYPES OBSERVED. TRANSCRIPTS PRODUCED BY POL III, INCLUDING TRNAS, HAVE BEEN SHOWN IN MULTIPLE SYSTEMS TO BE TISSUE-SPECIFICALLY EXPRESSED. TO GENERATE A NEW UNDERSTANDING OF THE ROLE OF POL III TRANSCRIPTION SPECIFICALLY IN NCC, I WILL RECEIVE TRAINING IN PROFILING NCC FOR CHANGES IN POL III TRANSCRIPTS AND IN EVALUATING THE EFFECT OF THESE CHANGES ON TRANSLATION. IT HAS BEEN POSTULATED THAT DISTINCT PATHOGENIC VARIANTS IN POLR3A, THE LARGEST SUBUNIT OF POL III, LEAD TO DIFFERENTIAL EFFECTS ON POL III TRANSCRIPTION. IN ORDER TO TEST THIS HYPOTHESIS IN A NCC- SPECIFIC MANNER, I WILL USE HIPSCS DERIVED FROM PATIENT FIBROBLASTS WITH PATHOGENIC VARIANTS IN POLR3A AND ANALYZE THEM FOR PROLIFERATION, TRANSLATION, DIFFERENTIATION, AND POL I AND III TRANSCRIPTION. GIVEN THE PREVALENCE OF DENTAL ANOMALIES IN INDIVIDUALS WITH MUTATIONS IN POLR3A, I EXPECT TO IDENTIFY POL III-SPECIFIC EFFECTS IN A SUBSET OF NCC DERIVATIVES. IN THE INDEPENDENT PHASE OF THIS AWARD, I WILL GENERATE NEW ZEBRAFISH MODELS TO UNDER- STAND THE ROLE OF SPECIFIC VARIANTS IN POL III IN A DEVELOPMENTAL CONTEXT AND ASSESS NCC FORMATION, MIGRATION, DIFFERENTIATION, AND PROLIFERATION IN COMBINATION WITH THE EFFECT ON POL I AND III TRANSCRIPTION. THESE MODELS WILL PROVIDE NEW RESOURCES TO THE RESEARCH COMMUNITY FOR THE UNDERSTANDING OF POL III TRANSCRIPTION. ALTOGETHER, I WILL RECEIVE THE TRAINING NECESSARY TO ANALYZE POL III TRANSCRIPTION AND TRANSLATION AND MODEL PATIENT-SPECIFIC VAR- IANTS IN NCC WHICH WILL FORM THE FOUNDATION OF MY INDEPENDENT RESEARCH PROGRAM AND FURTHER MY GOAL OF UNDER- STANDING AND PREVENTING CRANIOFACIAL BIRTH DEFECTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $249.0k | 3/24/25 | ||
| Not listed | $10.4k | 9/23/24 | ||
| Not listed | $10.4k | 9/23/24 | ||
| Not listed | $249.0k | 4/5/24 | ||
| Not listed | $249.0k | 4/5/24 |